Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Download Data

Monte Rosa Therapeutics Inc Non-current Assets to Total Assets Ratio for the quarter ending March 31, 2024: 0.25

Monte Rosa Therapeutics Inc Non-current Assets to Total Assets Ratio is 0.25 for the quarter ending March 31, 2024, a 14.56% change year over year. The non-current assets to total assets ratio measures the proportion of a company's non-current assets to its total assets. It is calculated by dividing the total non-current assets by the total assets. This ratio provides insights into the composition of a company's asset base and the extent to which it relies on non-current assets, such as property, plant, and equipment, to generate revenue. A higher ratio suggests a greater proportion of non-current assets, indicating potential long-term stability and investment in fixed assets.

Monte Rosa Therapeutics Inc Non-current Assets to Total Assets Ratio for the quarter ending March 31, 2023 was 0.22, a 199.02% change year over year.
Monte Rosa Therapeutics Inc Non-current Assets to Total Assets Ratio for the quarter ending March 31, 2022 was 0.07, a 50.44% change year over year.
Monte Rosa Therapeutics Inc Non-current Assets to Total Assets Ratio for the quarter ending March 31, 2021 was 0.05.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends